Royal Bank of Canada
JUNO

Royal Bank of Canada’s Juno Therapeutics, Inc. JUNO Stock Holding History

Royal Bank of Canada’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-124,679
Closed -$5.7M – 7207
2017
Q4 		$5.7M Buy
124,679
+122,250
+5,033% +$6.1M ﹤0.01% 1974
2017
Q3 		$109K Buy
2,429
+1,527
+169% +$52.1K ﹤0.01% 4955
2017
Q2 		$26K Sell
902
-4,899
-84% -$121K ﹤0.01% 5446
2017
Q1 		$129K Sell
5,801
-21,300
-79% -$457K ﹤0.01% 4609
2016
Q4 		$511K Buy
27,101
+21,309
+368% +$521K ﹤0.01% 3724
2016
Q3 		$175K Sell
5,792
-150
-3% -$4.67K ﹤0.01% 4520
2016
Q2 		$229K Sell
5,942
-347
-6% -$14.4K ﹤0.01% 4321
2016
Q1 		$239K Sell
6,289
-578
-8% -$20.1K ﹤0.01% 4247
2015
Q4 		$302K Sell
6,867
-13,421
-66% -$666K ﹤0.01% 4227
2015
Q3 		$827K Buy
20,288
+20,038
+8,015% +$879K ﹤0.01% 3040
2015
Q2 		$13K Sell
250
-9,380
-97% -$498K ﹤0.01% 5958
2015
Q1 		$585K Buy
9,630
+9,455
+5,403% +$459K ﹤0.01% 3365
2014
Q4 		$9K Buy
+175
New +$7.83K ﹤0.01% 5658

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

Royal Bank of Canada's JUNO Position: Q1 2018 in Review

Royal Bank of Canada sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 124,679 shares — an estimated $5.7M sold.

Royal Bank of Canada first reported a position in JUNO in Q4 2014 and held it in 13 quarters. The position peaked at $5.7M in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • Royal Bank of Canada reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Royal Bank of Canada sold 124,679 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $5.7M.
  • Royal Bank of Canada first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 13 quarters.
  • Royal Bank of Canada's Juno Therapeutics, Inc. position peaked at $5.7M in Q4 2017.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Royal Bank of Canada's 13F filing for Q1 2018, filed 15 May 2018.